Orexigen Climbs On Locaserin's Approval

Shares of Orexigen Therapeutics Inc. (Nasdaq: OREX) climbed again by gaining 84 cents to $5.76 after rival Arena Pharmaceuticals Inc.'s (Nasdaq: ARNA) weight loss treatment Lorcaserin was approved yesterday. Arena stock dropped $1.29 to $10.10 as investors locked in profits on the biopharmaceutical.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here